CMRX - Chimerix Inc Stock Price, Fair Value and News

0.95USD+0.01 (+1.06%)Market Closed

Market Summary

USD0.95+0.01

Market Closed

1.06%

CMRX Stock Price

View Fullscreen

CMRX RSI Chart

CMRX Valuation

Market Cap

85.1M

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

262.8

EV/EBITDA

0.35

Price/Free Cashflow

-1.32

CMRX Price/Sales (Trailing)

CMRX Profitability

Operating Margin

100.00%

EBT Margin

55028.09%

Return on Equity

-47.44%

Return on Assets

-42.56%

Free Cashflow Yield

-75.67%

CMRX Fundamentals

CMRX Revenue

Revenue (TTM)

324.0K

Rev. Growth (Yr)

-99.51%

Rev. Growth (Qtr)

-73.33%

CMRX Earnings

Earnings (TTM)

-82.6M

Earnings Growth (Yr)

-2.33%

Earnings Growth (Qtr)

-20.42%

Breaking Down CMRX Revenue

Last 7 days

4.4%

Last 30 days

-9.5%

Last 90 days

2.2%

Trailing 12 Months

-16.7%

How does CMRX drawdown profile look like?

CMRX Financial Health

Current Ratio

8.61

CMRX Investor Care

Shares Dilution (1Y)

1.18%

Diluted EPS (TTM)

-0.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	25.4M	17.1M	8.7M	324.0K
2022	9.9M	17.9M	25.9M	33.8M
2021	5.6M	4.6M	3.1M	2.0M
2020	10.7M	8.9M	7.2M	5.4M
2019	8.8M	9.0M	10.6M	11.6M
2018	4.2M	4.7M	4.2M	7.2M
2017	5.6M	4.4M	4.6M	4.5M
2016	10.8M	8.4M	6.8M	5.7M
2015	4.5M	7.7M	8.8M	10.8M
2014	3.4M	3.5M	3.8M	4.0M
2013	32.4M	27.0M	7.1M	4.4M
2012	17.5M	22.9M	28.3M	33.7M
2011	0	0	0	12.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Chimerix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 14, 2024	andriole michael t.	sold	-1,809	1.0375	-1,744	president and ceo
Feb 14, 2024	jakeman david	sold	-2,776	1.0439	-2,660	vp of finance and accounting
Feb 14, 2024	laspaluto michelle	sold	-2,022	1.0426	-1,940	chief financial officer
Feb 01, 2024	andriole michael t.	acquired	-	-	83,750	president and ceo
Feb 01, 2024	jakeman david	acquired	-	-	10,750	vp of finance and accounting
Feb 01, 2024	melemed allen s.	acquired	-	-	28,125	chief medical officer
Feb 01, 2024	laspaluto michelle	acquired	-	-	25,000	chief financial officer
Feb 01, 2024	alrutz michael albert	acquired	-	-	21,875	svp and general counsel
Dec 29, 2023	andriole michael t.	gifted	-	-	-17,000	president and ceo
Nov 17, 2023	middleton fred a	bought	16,521	0.9553	17,295	-

Which funds bought or sold CMRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 30, 2024	VANCE WEALTH, INC.	unchanged	-	3,814	50,159	0.02%
Apr 30, 2024	Joel Isaacson & Co., LLC	unchanged	-	3,281	35,662	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	new	-	11,000	11,000	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	19.00	212	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	90.16	12,000	22,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-8.69	2,284	411,831	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	244	2,650	-%
Apr 24, 2024	Assenagon Asset Management S.A.	reduced	-9.00	1,072	481,736	-%
Apr 23, 2024	BENDER ROBERT & ASSOCIATES	sold off	-100	-10,211	-	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	unchanged	-	4,212	45,792	-%

Are Funds Buying or Selling CMRX?

Are funds buying CMRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CMRX

No. of Funds

Unveiling Chimerix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ra capital management, l.p.	9.9%	8,800,000	SC 13G/A
Feb 12, 2024	rubric capital management lp	0%	0	SC 13G/A
Sep 29, 2023	ra capital management, l.p.	7.3%	6,501,624	SC 13G
Jul 07, 2023	blackrock inc.	1.3%	1,146,046	SC 13G/A
May 02, 2023	rubric capital management lp	5.39%	4,779,020	SC 13G
Feb 14, 2023	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 13, 2023	opaleye management inc.	0.0%	0	SC 13G/A
Feb 13, 2023	suvretta capital management, llc	0%	0	SC 13G/A
Feb 01, 2023	blackrock inc.	5.7%	5,030,867	SC 13G/A
Nov 10, 2022	rubric capital management lp	8.51%	7,500,000	SC 13D

Recent SEC filings of Chimerix Inc

View All Filings

Date Filed	Form Type	Document
May 01, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 21, 2024	3	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 21, 2024	8-K	Current Report
Feb 29, 2024	10-K	Annual Report
Feb 29, 2024	8-K	Current Report
Feb 29, 2024	S-3	S-3

Peers (Alternatives to Chimerix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	5.56%	-15.17%	-9.03	6.22	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.9B	1.8B	-2.25%	-24.69%	-42.88	10.32	76.23%	61.08%
BMRN	15.8B	2.5B	-4.35%	-11.20%	76.99	6.4	13.74%	186.89%
INCY	11.9B	3.8B	-6.50%	-24.30%	15.95	3.16	8.58%	129.81%
MID-CAP
APLS	5.6B	396.6M	-22.91%	-44.64%	-10.5	14	425.83%	18.94%
BBIO	4.8B	-	-9.87%	93.55%	-7.27	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-2.73%	5.06%	-14.83	13.11	440.80%	-27.84%
ARWR	2.9B	240.7M	-18.02%	-34.57%	-9.66	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.68%	-20.30%	-45.81	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.49%	-8.60%	25.07	4.5	85.90%	-14.05%
NVAX	652.2M	983.7M	0.22%	-33.81%	-1.2	0.66	-50.36%	17.16%
CRBP	390.9M	881.7K	-1.95%	364.46%	-8.76	466.16	-77.61%	-5.33%
INO	270.2M	4.9M	-11.89%	28.44%	-2	55.51	-54.97%	51.71%
IBIO	6.4M	2.1M	-44.78%	68.18%	-0.24	2.14	-13.45%	66.37%

Chimerix Inc News

Latest updates

Chimerix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q4	2019Q3	2019Q2
Revenue	-100.0%	-	4,000	15,000	26,000	420,000	814,000	32,555,000	21,718,667	10,882,333	46,000	107,000	391,000	1,435,000	1,120,000	1,609,000	1,402,000	1,241,000	1,480,000	1,719,000	1,958,000	1,438,000
Cost Of Revenue	-	-	-	-	-	-	-	333,000	-	114,000	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-100.0%	-	4,000	11,000	26,000	283,000	814,000	32,222,000	440,000	-99,000	46,000	107,000	391,000	1,435,000	-	-	-	-	-	-	-	-
Operating Expenses	17.2%	24,390,000	20,814,000	26,700,000	21,374,000	24,501,000	24,628,000	20,576,000	23,887,000	24,672,000	39,578,000	18,707,000	18,206,000	98,888,000	12,877,000	13,169,000	11,688,000	12,154,000	10,640,000	-	76,522,000	20,139,000
S&GA Expenses	-100.0%	-	5,170,000	9,304,000	4,448,000	5,679,000	5,347,000	5,313,000	5,840,000	5,632,000	5,241,000	4,887,000	4,408,000	4,136,000	4,190,000	3,151,000	3,110,000	3,205,000	3,147,000	-	4,024,000	6,312,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,827,000
EBITDA Margin	-0.2%	583	584	21.08	10.59	7.00	5.18	-6.69	-9.67	-17.40	-87.37	-14.11	-9.42	-	-	-	-	-	-	-	-	-
Interest Expenses	-4.8%	2,521,000	2,649,000	2,703,000	2,772,000	2,846,000	2,737,000	199,000	-21,000	4,000	34,000	40,000	52,000	38,000	82,000	149,000	270,000	493,000	370,000	-	834,000	1,051,000
Income Taxes	-	-	-	-	-	-	-117,000	153,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	100.0%	-	-18,161,000	-23,986,000	-	-	-21,077,000	241,515,000	-	-	-	-18,560,000	-	-	-	-	-	-	-	-	-	-
EBT Margin	0%	550	550	19.80	10.09	6.77	5.09	-6.70	-9.68	-17.43	-87.54	-14.26	-9.55	-	-	-	-	-	-	-	-	-
Net Income	-20.4%	-21,869,000	-18,161,000	-23,986,000	-18,576,000	-21,372,000	-20,960,000	241,362,000	-23,468,000	-24,767,000	-39,498,000	-18,560,000	-17,763,000	-97,415,000	-11,675,000	-11,411,000	-10,016,000	-10,420,000	-3,503,000	-	-73,730,000	-17,650,000
Net Income Margin	-0.6%	-254	-253	-9.76	10.57	6.90	5.09	5.94	-5.94	-10.12	-87.54	-47.63	-30.35	-	-	-	-	-	-	-	-	-
Free Cashflow	-20.3%	-17,545,000	-14,588,000	-17,948,000	-14,354,000	-22,287,000	-19,987,000	7,056,000	-10,560,000	-23,447,000	-34,037,000	-15,293,000	-12,836,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-8.8%	194	213	225	241	259	279	294	54.00	66.00	101	133	147	159	85.00	94.00	102	108	119	128	163	178
Current Assets	-13.8%	163	189	201	212	225	228	291	51.00	63.00	96.00	129	136	148	82.00	90.00	99.00	107	118	126	161	176
Cash Equivalents	-31.2%	19.00	28.00	14.00	20.00	16.00	26.00	274	28.00	32.00	15.00	26.00	25.00	32.00	47.00	38.00	54.00	25.00	17.00	19.00	22.00	20.00
Inventory	-	-	-	-	-	-	-	-	4.00	3.00	3.00	2.00	-	-	-	-	-	-	-	-	-	-
Net PPE	17.4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00
Liabilities	1.0%	20.00	20.00	17.00	17.00	18.00	22.00	20.00	26.00	18.00	32.00	29.00	28.00	25.00	11.00	10.00	9.00	7.00	9.00	16.00	14.00	14.00
Current Liabilities	2.7%	19.00	18.00	16.00	15.00	16.00	20.00	18.00	23.00	15.00	30.00	26.00	25.00	22.00	9.00	7.00	6.00	7.00	9.00	15.00	14.00	13.00
Shareholder's Equity	-9.8%	174	193	208	224	240	257	274	28.00	48.00	68.00	105	119	134	73.00	83.00	93.00	101	110	112	149	164
Retained Earnings	-2.7%	-817	-795	-777	-753	-734	-713	-692	-933	-910	-885	-846	-827	-809	-712	-700	-689	-679	-668	-665	-591	-573
Additional Paid-In Capital	0.3%	992	988	986	978	975	971	966	962	958	954	951	947	943	786	784	782	780	779	777	741	738
Shares Outstanding	0.8%	90.00	89.00	89.00	89.00	89.00	88.00	87.00	87.00	87.00	85.00	86.00	86.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	94.00	-	-	-	111	-	-	-	579	-	-	-	136	-	-	-	137	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-20.1%	-17,518	-14,588	-17,933	-14,342	-22,225	-19,988	7,128	-10,560	-23,447	-34,023	-15,288	-12,723	-37,896	-9,045	-8,299	-7,874	-10,820	-3,469	-42,161	-13,817	-15,734
Share Based Compensation	22.0%	2,749	2,253	7,880	2,961	4,363	4,165	3,819	3,593	3,708	3,133	3,431	3,112	2,584	1,568	1,283	1,391	1,326	1,559	1,529	2,367	4,073
Cashflow From Investing	-69.1%	8,675	28,069	11,874	18,521	12,135	-228,399	238,269	6,700	53,467	23,194	15,460	5,971	-88,716	17,558	-7,332	36,244	18,243	1,020	39,700	15,738	-45,827
Cashflow From Financing	235.5%	208	62.00	78.00	-31.00	199	-32.00	778	-11.00	-13,460	52.00	557	117	111,703	346	260	578	229	1.00	166	18.00	160

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CMRX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 324,000	$ 33,824,000	$ 1,979,000
Cost of goods sold	0	447,000	0
Gross Profit	324,000	33,377,000	1,979,000
Operating expenses:
Research and development	68,788,000	71,631,000	73,817,000
General and administrative	24,601,000	22,132,000	18,672,000
Acquired in-process research and development	0	0	82,890,000
Total operating expenses	93,389,000	93,763,000	175,379,000
Loss from operations	(93,065,000)	(60,386,000)	(173,400,000)
Other income:
Interest income and other, net	10,970,000	2,919,000	164,000
Gain on sale of business, net	0	229,670,000	0
(Loss) income before income taxes	(82,095,000)	172,203,000	(173,236,000)
Income tax expense	0	36,000	0
Net (loss) income	(82,095,000)	172,167,000	(173,236,000)
Other comprehensive income (loss):
Unrealized gain (loss) on debt investments, net	344,000	(316,000)	(21,000)
Comprehensive (loss) income	$ (81,751,000)	$ 171,851,000	$ (173,257,000)
Per share information:
Net (loss) income, basic (in dollars per share)	$ (0.93)	$ 1.97	$ (2.04)
Net (loss) income, diluted (in dollars per share)	$ (0.93)	$ 1.94	$ (2.04)
Weighted-average shares outstanding, basic (in shares)	88,604,026	87,555,110	84,930,255
Weighted-average shares outstanding, diluted (in shares)	88,604,026	88,776,147	84,930,255
Procurement revenue
Revenues:
Total revenues	$ 0	$ 31,971,000	$ 0
Contract and grant revenue
Revenues:
Total revenues	275,000	942,000	1,928,000
Licensing revenue
Revenues:
Total revenues	49,000	536,000	51,000
Royalty revenue
Revenues:
Total revenues	$ 0	$ 375,000	$ 0

CMRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 27,661	$ 25,842
Short-term investments, available-for-sale	155,174	191,492
Accounts receivable	4	1,040
Prepaid expenses and other current assets	6,271	9,764
Total current assets	189,110	228,138
Long-term investments	21,657	48,626
Property and equipment, net of accumulated depreciation	224	227
Operating lease right-of-use assets	1,482	1,964
Other long-term assets	301	386
Total assets	212,774	279,341
Current liabilities:
Accounts payable	2,851	3,034
Accrued liabilities	15,592	17,381
Total current liabilities	18,443	20,415
Line of credit commitment fee	125	250
Lease-related obligations	1,177	1,819
Total liabilities	19,745	22,484
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022; 88,929,300 and 88,054,127 shares issued and outstanding at December 31, 2023 and 2022, respectively	89	88
Additional paid-in capital	988,457	970,535
Accumulated other comprehensive gain (loss), net	7	(337)
Accumulated deficit	(795,524)	(713,429)
Total stockholders’ equity	193,029	256,857
Total liabilities and stockholders’ equity	$ 212,774	$ 279,341

About Chimerix Inc

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

CEO	Mr. Michael T. Andriole M.B.A.
WEBSITE	chimerix.com
INDUSTRY	Biotechnology
EMPLOYEES	89

Chimerix Inc Frequently Asked Questions

What is the ticker symbol for Chimerix Inc? What does CMRX stand for in stocks?

CMRX is the stock ticker symbol of Chimerix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Chimerix Inc (CMRX)?

As of Wed May 01 2024, market cap of Chimerix Inc is 84.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CMRX stock?

You can check CMRX's fair value in chart for subscribers.

What is the fair value of CMRX stock?

You can check CMRX's fair value in chart for subscribers. The fair value of Chimerix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Chimerix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CMRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Chimerix Inc a good stock to buy?

The fair value guage provides a quick view whether CMRX is over valued or under valued. Whether Chimerix Inc is cheap or expensive depends on the assumptions which impact Chimerix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CMRX.

What is Chimerix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 01 2024, CMRX's PE ratio (Price to Earnings) is -1.03 and Price to Sales (PS) ratio is 261.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CMRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Chimerix Inc's stock?

In the past 10 years, Chimerix Inc has provided -0.256 (multiply by 100 for percentage) rate of return.